6.04
-2.74%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tiansheng Pharmaceutical Group Co
Its shares trade on Shenzhen under the ticker 002872.SZ. It has been listed since 19 May 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥514.1m and a net loss of CN¥55.4m. At that date it held total assets of CN¥2.64bn and shareholders' equity of CN¥1.95bn.
Tiansheng Pharmaceutical Group Co., Ltd. is a holding company that manufactures pharmaceutical products. The company is headquartered in Chongqing, Chongqing. The company went IPO on 2017-05-19. The firm's main products include pediatric lung cough particles, erythromycin enteric-coated capsules, silver ginseng Tongluo capsules, Salvia granules, Shugan Yi spleen granules, compound Ganoderma lucidum granules, Xiangdan injection, Injection, Qi and Diabetes tablets, liver capsule, Ling Jing capsule, lungs of nuclear paste, Shen Qi Yi lung pill, among others. The firm mainly distributes its products within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 May 2017
- Employees
- 1,330
- Website
- tszy.com.cn ↗
Leadership
Pay as last reported
- Hong LiGeneral Manager & Director
- Kai sheng WangChief Financial Officer
- Hai Tian XiongDirector & Deputy General Manager
- Wei LiuChairman & Deputy General Manager
- Xiao Hong ChenChairman-Supervisory Board
- Hong LiGeneral Manager & Director
- Rui Peng Deng, PhDIndependent Director, since 2017
- Yong Du, PhDIndependent Director, since 2017
- Shao Liang JiIndependent Director, since 2017
- Mei ZhongMember-Supervisory Board, since 2017
- Yan LuoMember-Supervisory Board, since 2017
- Guo Tai TangMember-Supervisory Board, since 2017
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tiansheng Pharmaceutical Group employs 1330 employees in Chongqing for pharmaceutical manufacturing.
- The company's main products include pediatric lung cough particles and erythromycin enteric-coated capsules.
- Tiansheng Pharmaceutical Group distributes its products primarily within the domestic market in China.
Weaknesses
- The company has no international presence beyond China's domestic market.
- Tiansheng Pharmaceutical Group's product portfolio lacks diversity in global markets.
- The firm's IPO was in 2017, indicating limited market experience.
Opportunities
- Expanding into international markets could leverage Tiansheng's pharmaceutical expertise.
- Growing demand for traditional Chinese medicine products presents a market opportunity.
- Increasing healthcare spending in China supports Tiansheng's domestic market growth.
Threats
- Competition from other Chinese pharmaceutical companies in the domestic market.
- Regulatory changes in China's pharmaceutical industry could impact operations.
- Economic downturns in China may reduce healthcare spending.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.